Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.

ABSTRACT:

Background

There are two US Food and Drug Administration (FDA)-approved drugs, pirfenidone and nintedanib, for treatment of patients with idiopathic pulmonary fibrosis (IPF). However, neither of these drugs provide a cure. In addition, both are associated with several drug-related adverse events. Hence, the pursuit for newer IPF therapeutics continues. Recent studies show that joint analysis of systems-biology-level information with drug-disease connectivity are effective in discovery of biologically relevant candidate therapeutics.

Methods

Publicly available gene expression signatures from patients with IPF were used to query a large-scale perturbagen signature library to discover compounds that can potentially reverse dysregulated gene expression in IPF. Two methods were u

SUBMITTER: Wang Y 

PROVIDER: S-EPMC7659024 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature